Abeona Therapeutics Inc (ABEO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.57 (-0.36%), Market cap $0.26B, P/E ratio 4.53, 52-week low–high $4.17 ~ $7.23.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. w
Financial statements, price targets, institutional (13F) holdings and related news for Abeona Therapeutics Inc are updated in real time on BlackAll Trade.
Abeona Therapeutics Inc trades at $5.57 (-0.36%). Real-time quotes and charts are available on BlackAll Trade.
Abeona Therapeutics Inc has a market cap of about $0.26B. Its P/E ratio is 4.53.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. It develops ZEVASKYN, an autologous, cell-based gene therapy for